To examine the roles of PLD (phospholipase D) in the regulation of the apoptotic process, PLD1 and PLD2 were stably overexpressed in S1P 3 -CHO cells [CHO (Chinese-hamster ovary) cells expressing the S1P (sphingosine 1-phosphate) receptor S1P 3 ]. Treatment of S1P 3 -CHO cells with ActD (actinomycin D) induced apoptosis, as shown by the occurrence of nuclear fragmentation and the caspase-dependent proteolytic cleavage of PARP [poly(ADP-ribose) polymerase] and protein kinase Cδ. Overexpression of either PLD1 or PLD2 protected S1P 3 -CHO cells from ActD-induced apoptosis, as demonstrated by an increased number of viable cells and inhibition of PARP and protein kinase Cδ cleavage. However, in the early phase of apoptosis, ActD induced an increase in PLD activity and activation of key factors in the cell-survival signalling pathways, such as PI3K (phosphoinositide 3-kinase), Akt, p70S6K (p70 S6 kinase) and ERK (extracellular-signal-regulated kinase). Furthermore, the ActD-induced activation of these survival signalling enzymes was potentiated by overexpression of either PLD1 or PLD2. The PI3K inhibitor LY294002 inhibited the ActD-induced activation of Akt and p70S6K, and completely abolished the effects of PLD1 or PLD2, whereas inhibition of ERK activity by the MEK inhibitor U0126 had a milder effect. The ActD-induced activation of p70S6K and ERKs was blocked by 1-butanol, but not by t-butanol; similar to S1P, exogenous PLD suppressed the ActDinduced events in the apoptosis signalling pathways. These results show that, in S1P 3 -CHO cells, increased expression of PLDs prevents ActD-induced apoptosis by enhanced activation of the PI3K signalling pathways.
INTRODUCTION
In response to a variety of cell stimuli, PLD (phospholipase D) cleaves phosphatidylcholine, generating PtdOH (phosphatidic acid), which plays a crucial role in the regulation of several important biological events via the activation of PI4P5K (phosphoinositide 4-phosphate 5-kinase) [1] , mTOR (mammalian target of rapamycin) [2] and PKCζ (protein kinase Cζ ) [3] , and Raf-1 translocation [4] . However, the physiological roles of PLD have not been elucidated completely. Two mammalian PLD genes, PLD1 and PLD2, have been cloned [5] . PLD1 activity is regulated by PKC and low-molecular-mass GTP-binding proteins, such as ADP-ribosylation factor and the Rho family proteins [6, 7] . PLD2 is constitutively active in vitro, but requires PtdIns(4,5)P 2 as a cofactor [5] [6] [7] [8] ; however, the mechanisms that regulate its activity in vivo remain undefined. Cellular PLD activity is increased in response to treatment of various mammalian cells with mitogenic stimuli [7, 9] . Recent studies have demonstrated that both PLD1 and PLD2 play a role in insulin or lysoPtdOH (lysophosphatidic acid) receptor-mediated activation of ERK (extracellular-signalregulated kinase) via Raf-1 translocation to membranes [4, 10] . A study by Fang et al. [2] implicated the PtdOH generated by PLD activation in the mTOR signalling cascade involving p70S6K (p70 Abbreviations used: ActD, actinomycin D; CHO cells, Chinese-hamster ovary cells; EDG, endothelial differentiation gene; ERK, extracellular-signalregulated kinase; IGF-1, insulin-like growth factor 1; MEK, mitogen-activated protein kinase kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; mTOR, mammalian target of rapamycin; p70S6K, p70 S6 kinase; PARP, poly(ADP-ribose) polymerase; PI3K, phosphoinositide 3-kinase; PI4P5K, phosphoinositide 4-phosphate 5-kinase; PKCδ, protein kinase Cδ; PLD, phospholipase D; PLDSc, Streptomyces chromofuscus PLD; PtdBut, phosphatidylbutanol; PtdOH, phosphatidic acid; lysoPtdOH, lysophosphatidic acid; S1P, sphingosine 1-phosphate; S1P 3 -CHO cells, CHO cells expressing the S1P receptor S1P 3 ; Z-Val-Ala-DL-Asp-CH 2 F, benzyloxycarbonyl-valylalanyl-DL-aspartylfluoromethane. 1 To whom correspondence should be addressed (e-mail banno@cc.gifu-u.ac.jp).
S6 kinase)
. PLD activity is significantly increased in cancer cells and tissues [11] [12] [13] , suggesting that it plays an important role in the signal transduction pathways associated with cell proliferation and carcinogenesis [7, 9, 14] , and it is therefore assumed that PLD provides a proliferation signal that facilitates the overriding need of cell-cycle checkpoints [15, 16] . A growing body of evidence suggests that S1P (sphingosine 1-phosphate) is a member of a new class of lipid mediators derived from the metabolism of sphingolipids, and five closely related G-protein-coupled receptors of the EDG (endothelial differentiation gene) family, namely EDG1/S1P1, EDG3/S1P3, EDG5/ S1P2, EDG6/S1P4 and EDG8/S1P5, are identified as plasmamembrane receptors for S1P [17] [18] [19] . The potential role of S1P in cellular growth and survival has also been suggested by its ability to decrease ceramide-and serum withdrawal-induced apoptosis [20, 21] . ERKs and Akt are supposed to play a pivotal role in cellproliferation and cell-survival signalling pathways. Our previous studies have shown that PLD is involved in S1P 3 (S1P receptor)-mediated PI3K (phosphoinositide 3-kinase)/Akt activation and also in S1P-and IGF-1 (insulin-like growth factor 1)-induced ERK activation [22, 23] . These results suggest that PLDs are involved in cell survival and proliferation via the regulation of at least two signalling pathways, PI3K/Akt and Ras/ERKs. PLD activity has been shown to increase in various cells at the early stage of the apoptotic process [24] . Several studies have reported that increased PLD activity prevents the apoptosis induced in PC12 cells by H 2 O 2 or hypoxia [25, 26] and in v-src-transformed fibroblasts [27] . However, little is known about how PLD rescues cells from apoptosis. In the present study, we have demonstrated that overexpression of PLD1 or PLD2 prevented ActD (actinomycin D)-induced apoptosis in S1P 3 -CHO cells [S1P 3 -expressing CHO (Chinese-hamster ovary) cells] via the activation of survival signalling pathways involving PI3K, Akt, p70S6K and ERKs.
MATERIALS AND METHODS

Materials
Geneticin (G418) and ActD were obtained from Sigma (St. Louis, MO, U.S.A.), pCMV-zeo and Zeocin from Invitrogen (Groningen, The Netherlands), S1P, PtdIns and PLDSc (Streptomyces chromofuscus PLD) from Matreya (Pleasant Gap, PA, U.S.A.) and [9, and β-actin and mouse monoclonal antibody raised against PKCδ were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Rabbit polyclonal anti-PLD1 and anti-PLD2 antibodies were prepared as described previously [28] . Anti-rabbit and antimouse IgG antibodies conjugated with horseradish peroxidase and the enhanced-chemiluminescence kit (ECL ® system) were obtained from Amersham Biosciences (Little Chalfont, Bucks., U.K.). Expression plasmids containing wild-type and catalytically negative human PLD1 and mouse PLD2 in pCGN were kindly supplied by Dr Michael A. Frohman (Department of Pharmacology and The Center for Developmental Genetics, University Medical Center at Stony Brook, New York, NY, U.S.A.). All other reagents were obtained from standard commercial sources.
Cell culture and transfections
CHO-K1 (CHO) cells overexpressing S1P 3 (S1P 3 -CHO cells) were cultured in Ham's F-12 medium, supplemented with 10 % (v/v) foetal bovine serum, 100 units/ml penicillin G, 100 µg/ml streptomycin and 0.75 mg/ml G418 as described previously [29] . Stable transfection of S1P 3 -CHO cells with PLD1 or PLD2 was performed as described previously [23] . Cells were serum-starved in serum-free Ham's F-12 medium for 24 h before treatment with ActD.
Measurement of PLD activity
Subconfluent cells were labelled for 24 h with 1 µCi/ml [ 3 H]palmitic acid in serum-free Ham's F-12 medium, washed, preincubated for 10 min in Hepes-Tyrode buffer containing 0.3 % (v/v) 1-butanol and incubated for 5 min with 1 µM S1P. Then, the reaction was stopped by removing the assay buffer, followed by the immediate addition of 1 ml of an ice-cold PBS/methanol (2:5, v/v) mixture to the culture dishes. Cellular lipids were then extracted and [ 3 H]phosphatidylbutanol (PtdBut) as a parameter of PLD activity was separated by TLC to measure its radioactivity, as described previously [28] .
PI3K assay
PI3K activity was assayed as described previously [23] . Immunoprecipitation was performed using anti-phosphotyrosine (PY-20) antibodies and PI3K activity was assayed using PtdIns as the substrate.
Western-blot analysis
Cells were grown to subconfluence in growth medium on 100 mm dishes and incubated for 24 h in serum-free Ham's F-12 medium before treatment for the indicated time with 2 µM ActD. The cells were then harvested in ice-cold lysis buffer (1 % Nonidet P40/0.5 % sodium cholate/1 mM EDTA/1 mM EGTA/150 mM NaCl/20 mM Hepes/3 mM MgCl 2 /1 mM PMSF/20 µg/ml leupeptin/20 mM β-glycerophosphate/1 mM sodium fluoride/1 mM sodium orthovanadate, pH 7.4) and sonicated. Protein concentrations were determined using the Bradford protein assay reagent (Bio-Rad Laboratories) with BSA as the standard. The total cell lysate (50-100 µg of protein) was subjected to SDS/PAGE (10 % gel) and then transferred on to PVDF membranes (Millipore). The membranes were blocked using 5 % (w/v) BSA. Phosphorylation of Akt, p70S6K and ERK was measured by immunoblotting with rabbit polyclonal antibodies specific for Ser 473 -phosphorylated Akt, Thr 421 /Ser 424 -phosphorylated p70S6K or Tyr 204 -phosphorylated ERK1/ERK2 respectively. Total amounts of Akt, p70S6K and ERK were determined by immunoblotting with rabbit polyclonal antibodies raised against Akt, p70S6K or ERK respectively. Cleavage of PKCδ and PARP was examined by Western-blot analysis using antibodies raised against PKCδ or PARP and horseradish peroxidase-linked secondary antibody. Anti-β-actin antibody was used as loading control. After repeated washes, bound antibodies were detected using the ECL ® Westernblotting detection system.
Cytotoxicity assay
The cytotoxic effect of ActD on S1P 3 -CHO cells was measured using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay [30] . Cells (3 × 10 3 in 100 µl/well) were plated in triplicate on 96-well plates overnight in the complete Ham's F-12 medium and were serum-starved in serum-free Ham's F-12 medium for 24 h. After treatment with 2 µM ActD for the indicated times, cell viability was determined by the MTT method.
Morphological examination
After S1P 3 -CHO cells were treated with 2 µM ActD for 9 h, they were trypsinized, washed, fixed by resuspension in 1 % glutaraldehyde solution for 30 min, rinsed in PBS, stained with Hoechst 33342 for 2 min and examined under a fluorescence microscope (Olympus BX60) with excitation at 360 nm.
RESULTS
Actinomycin D induces apoptotic cell death in S1P 3 -CHO cells
It has been reported that ActD induces apoptosis in Jurkat and pancreatic cancer cells [31, 32] . We first examined the effect of ActD on S1P 3 -CHO cell viability using the MTT cell growth assay, which has been often used to monitor cell proliferation. When S1P 3 -CHO cells were treated with either ActD, ceramide, H 2 O 2 , sphingosine or cycloheximide, ActD was found to be the most potent in decreasing cell viability (results not shown). When S1P 3 -CHO cells were treated with ActD for 12 h, a dosedependent decrease in cell viability was seen and a decrease of 70 % was observed at 2 µM ActD ( Figure 1A ). When the cells (A) S1P 3 -CHO cells were incubated with 2 µM ActD for the indicated time. (B) S1P 3 -CHO cells were incubated for 1 h with or without Z-Val-Ala-DL-Asp-CH 2 F (100 µM) and then for 9 h with 2 µM ActD. Cell lysates were subjected to Western-blot analysis using antibodies raised against PARP and PKCδ as described in the Materials and methods section. β-Actin was used as the loading control. The results are representative of three independent experiments. (C) S1P 3 -CHO cells were pretreated for 1 h with or without 100 µM Z-Val-Ala-DL-Asp-CH 2 F and then treated for 12 h with 2 µM ActD before cell viability was determined by the MTT assay, as described in the Materials and methods section. Results are expressed as the means + − S.E.M. for three different experiments.
were treated for various times with 2 µM ActD, cell viability decreased in a time-dependent manner, with 90 % cell death after 24 h incubation ( Figure 1B ). These results show that ActD induced dose-and time-dependent cell death in S1P 3 -CHO cells. Microscopic examination of ActD-treated cells showed that they became round and detached. After 9 h incubation with 2 µM ActD, 50 % of the cells remained attached. When the attached and detached cells were collected and examined by fluorescence microscopy after staining with Hoechst 33342, we observed nuclear fragmentation and condensation, which are characteristic of apoptosis ( Figures 1C and 1D) .
Recent studies have shown that both PKCδ and PARP are endogenous substrates for caspase 3, which cleaves PARP and PKCδ to yield 85 and 40 kDa catalytically active fragments respectively [33, 34] . As shown in Figure 2 (A), treatment with 2 µM ActD caused a time-dependent decrease in the amount of procaspase 3, concurrent with increases in cleaved PARP and PKCδ, as determined by Western-blot analysis. The PKCδ (40 kDa) and PARP (81 kDa) cleavage products were first seen after 6 h treatment and their cleavages were increased up to 12 h. Both caspase 3 activation and cleavage of PKCδ and PARP after 9 h of ActD treatment were completely blocked by pretreatment of the cells for 1 h with Z-Val-Ala-DL-Asp-CH 2 F (benzyloxycarbonyl-valylalanyl-DL-aspartylfluoromethane; 100 µM), a broad-spectrum caspase inhibitor ( Figure 2B ). Similar results were obtained by pretreatment with a caspase 3 inhibitor DEVD-FMK, where FMK stands for fluoromethylketone (results not shown). In addition, as shown in Figure 2 (C), cell viability was decreased to < 40 % after 12 h incubation with 2 µM ActD, but only to approx. 80 % when the cells were pretreated for 1 h with 100 µM Z-Val-Ala-DL-Asp-CH 2 F. These results indicate that ActD induced caspase 3-dependent apoptosis involving the cleavage of PARP and PKCδ in S1P 3 -CHO cells.
Overexpression of PLD1 or PLD2 prevents ActD-induced apoptosis in S1P 3 -CHO cells
To examine the role of PLD in survival signalling in response to apoptotic inducers, we established S1P 3 -CHO cells overexpressing PLD isoforms. Western-blot analysis using specific anti-PLD1 and anti-PLD2 antibodies confirmed the overexpression of PLD1WT (wild-type PLD1) and PLD2WT and their catalytically inactive mutants [PLD1KR (PLD1-K898R) and PLD2KR (PLD2-K758R); Figure 3A ]. As shown in Figure 3 (B), S1P-stimulated PLD activity as measured by PtdBut production was 4-and 3-fold higher in PLD1WT-and PLD2WT-overexpressing S1P 3 -CHO cells respectively compared with vector-transfected control cells, and the basal PtdBut production was 2-or 3-fold higher respectively compared with vector-transfected control cells. In contrast, in cells overexpressing either PLD1KR or PLD2KR, neither basal nor stimulated PtdBut production was increased. Furthermore, 6 h treatment with 2 µM ActD caused significant increases in S1P-stimulated PtdBut production in PLD1WT-and PLD2WT-overexpressing S1P 3 -CHO cells, but caused modest increases in vector-transfected control cells ( Figure 3C ). The expression levels of PLD1 and PLD2 were not altered after treatment with 2 µM ActD for 6 h ( Figure 3D ). These results indicated that the increase in PLD activity after treatment with ActD was not due to alteration of protein expression levels of PLD1 and PLD2. However, the mechanism underlying ActDinduced PLD activation is not known. As shown in Figure 4 , 12 h treatment with 2 µM ActD decreased the viability of control cells, PLD1KR-and PLD2KR-overexpressing cells by 70 %; however, decreases in the viability were much lower in the cells overexpressing PLD1WT and PLD2WT. The higher viability in the PLD1WT transfectants was consistent with the greater increase in PLD activation caused by S1P stimulation compared with PLD2WT-overexpressing cells ( Figure 3B) .
The ActD-induced proteolytic cleavage of PARP and PKCδ was markedly decreased in cells overexpressing PLD1WT and PLD2WT ( Figure 5 ), but not in cells overexpressing PLD1KR After serum starvation for 24 h, vector-transfected, PLD1WT-, PLD1KR-, PLD2WT-or PLD2KR-overexpressing S1P 3 -CHO cells were incubated for 12 h with the indicated concentration of ActD and cell viability was determined by the MTT assay as described in the Materials and methods section. Results are expressed as the means + − S.E.M. for three different experiments.
or PLD2KR (results not shown). This indicates that increased expression of either PLD1WT or PLD2WT exerted a preventive effect on ActD-induced apoptosis. Vector-transfected, PLD1WT-or PLD2WT-overexpressing S1P 3 -CHO cells were incubated for 9 h with or without 2 µM ActD and the cell lysates were subjected to Western-blot analysis using antibodies raised against PARP (upper panel) and PKCδ (lower panel) as described in the Materials and methods section. The results are representative of three independent experiments.
Effect of PLD1 and PLD2 overexpression on survival signalling pathway in ActD-treated cells
We have demonstrated previously that PLD is involved in the stimulation of PI3K/Akt and ERK survival signalling pathways in S1P-and IGF-1-treated S1P 3 -CHO cells [22, 23] . In the present study, we examined whether ActD treatment induces PI3K activation in S1P 3 -CHO cells. As shown in Figure 6 (A), treatment of the cells with 2 µM ActD for 6 h resulted in a significant increase in the PI3K activity in vector-transfected, PLD1WT-and PLD2WT-overexpressing cells. Furthermore, both basal and ActD-induced PI3K activities of cells overexpressing either PLD1WT or PLD2WT were significantly higher compared with the vector-transfected control cells. We then examined whether enhanced expression of PLD1 and PLD2 affected the survival signalling pathway in ActD-treated S1P 3 -CHO cells. Treatment of vector-transfected cells with 2 µM ActD for various time intervals resulted in the activation of Akt, p70S6K and ERK at the early stage of the apoptotic process ( Figure 6B ). In cells overexpressing PLD1WT and PLD2WT, the basal and ActDinduced phosphorylation levels of Akt, p70S6K and ERK were significantly higher compared with that in vector-transfected control cells ( Figure 6C ). Overexpression of PLD1WT and PLD2WT had no effect on the total expression levels of these survival signalling enzymes. Next, to determine whether the ActD-induced activation of Akt, p70S6K and ERK plays a preventive role in ActD-induced apoptosis, the effects of inhibitors on their upstream activators PI3K and MEK (mitogen-activated protein kinase kinase) were examined. Pretreatment of vector-transfected cells with the PI3K inhibitor LY294002 (10 µM) for 1 h completely inhibited the ActD-induced activation of Akt and p70S6K, whereas the MEK inhibitor U0126 (10 µM) was less effective in the suppression of ERK activation ( Figure 7A ). Pretreatment with the MEK inhibitor U0126 (10 µM) completely inhibited the ActD-induced ERK activation, but did not inhibit the Akt and p70S6K activation. In addition, LY294002 pretreatment resulted in increased ActDinduced cleavage of PARP and PKCδ ( Figure 7A ). Under the same conditions, the decrease in cell viability caused by ActD was increased by LY294002 pretreatment, whereas U0126 (10 µM) had a milder effect ( Figure 7B ). The effect of pretreatment (A) Vector-transfected, PLD1WT-or PLD2WT-overexpressing cells were incubated without or with 2 µM ActD for 6 h and the cell lysates were assayed for PI3K activity as described in the Materials and methods section. (B) Vector-transfected cells were incubated with 2 µM ActD for the indicated times and the cell lysates were subjected to Western-blot analysis using antibodies raised against phosphorylated Akt (P-Akt), phosphorylated p70S6K (P-p70S6K) and phosphorylated ERK (P-ERK1/ERK2) as described in the Materials and methods section. (C) Vector-transfected, PLD1WT-or PLD2WT-overexpressing cells were incubated with or without 2 µM ActD for 6 h and the cell lysates were subjected to Western-blot analysis as in (B). The results are representative of three independent experiments. with LY294002 or U0126 was also examined in PLD1-or PLD2-overexpressing cells that are resistant to the apoptosis. Pretreatment with 10 µM LY294002 for 1 h completely blocked the protective effect of overexpression of PLD1WT and PLD2WT, but 10 µM U0126 was less effective ( Figure 7C ). (A) Vector-transfected cells were incubated for 1 h with or without 10 µM LY294002 or U0126 and then for 6 h with or without 2 µM ActD. Cell lysates were subjected to Western-blot analysis using antibodies raised against phosphorylated Akt, phosphorylated p70S6K, phosphorylated ERK, Akt, p70S6K, ERK, PARP or PKCδ as described in the Materials and methods section. β-Actin was used as a loading control. The results are representative of three independent experiments. (B) Vector-transfected cells were incubated for 1 h with or without either 10 µM LY294002 or U0126 and then for 12 h with 2 µM ActD. Then, cell viability was measured by the MTT assay as described in the Materials and methods section. (C) Vector-transfected or PLD1WT-or PLD2WT-overexpressing S1P 3 -CHO cells were incubated for 1 h with or without either 10 µM LY294002 or U0126 and then for 12 h with 2 µM ActD. Results are expressed as the means + − S.E.M. for three different experiments. *P < 0.05 compared with control.
To gain more insight into the link between PLD and the survival signalling pathway, we examined the effects of 1-butanol; PtdOH formation by the PLD pathway is prevented in the presence of 1-butanol by transphosphatidylation of the reaction products to the phospholipid PtdBut. Pretreatment of S1P 3 -CHO cells with 0.5 % 1-butanol for 30 min caused great inhibition of ActD-induced phosphorylation of p70S6K and ERK, but the same concentration of t-butanol, an inactive analogue for PLDmediated PtdOH formation, had no effect ( Figure 8A ). We have shown previously that treatment of S1P 3 -CHO cells with PLDSc resulted in increased generation of PtdOH, as observed in S1P stimulation [22] . As shown in Figure 8 (B), pretreatment with either 1 µM S1P or 10 units/ml PLDSc suppressed the ActDinduced proteolytic cleavage of PARP and PKCδ. Although it is generally accepted that PLD action may be mediated by PtdOH acting as a second messenger, it has been reported that exogenous PLD action is mediated by LysoPtdOH derived from pre-existing lysophosphatidylcholine [35] . However, LysoPtdOH had no significant effects on these proteolytic cleavages (results not shown). These results suggest that PtdOH generated by PLD activation may play a role in the ActD-induced activation of these survival enzymes, leading to prevention of apoptosis.
DISCUSSION
In the present study, we examined the role of PLD1 and PLD2 in cell-survival signalling and apoptosis in S1P 3 -CHO cells and found that overexpression of either PLD1 or PLD2 resulted in suppression of ActD-induced apoptosis. Several lines of evidence indicate that PLD activity changes in response to apoptotic stimuli (for a review see [24] ). PLD activity is down-regulated during ceramide-induced apoptosis in the human keratinocyte cell line HaCaT [36] . On the other hand, PLD activity increases during tumour necrosis factor-induced or anti-Fas antibody-induced apoptosis in A20 cells [37] , ActD-induced apoptosis in Jurkat T-cells [31] and camptothecin-induced apoptosis in HL60 cells [38] . These findings suggest that PLD activity is somehow involved in the apoptosis signalling. However, they have not provided a pertinent interpretation for the pro-or anti-apoptotic role(s) of PLD activity. Our previous studies demonstrated that the PLD activities in PC12 cells were increased at the early stage of the apoptotic process induced by hypoxia [26] and H 2 O 2 [39] . It was also shown that H 2 O 2 -or hypoxia-induced apoptosis was suppressed by transfection of PLD2 into PC12 cells [25, 26] . These observations indicate that PLD activation may play an antiapoptotic or pro-survival role. A recent report also demonstrates that increased expression of PLD1 or PLD2 suppresses serumwithdrawal-induced cell death in Raf-expressing NIH 3T3 cells, suggesting that PLD provides signals that overcome the cellcycle arrest induced by overexpression of Raf [16] . Although the exact mechanism by which PLD contributes to cell survival is unknown, it appears to be involved in the generation of survival and mitogenic signalling events. A study of PLD transformation showed up-regulation of the cell-cycle-regulatory protein, cyclin D3, an activator of the G 1 to S phase transition [15] . More recently, it has been demonstrated that activation of either PLD1 or PLD2 represses the expression of the gene for the cyclin-dependent kinase inhibitor p21 [40] . These findings led us to assume that PLD prevented ActD-induced apoptosis by increasing the levels of mitogenic cell-cycle-regulatory protein(s) or anti-apoptotic protein(s). However, no significant changes were observed in the expression of apoptosis-regulating proteins, such as Bax, Bcl-2, p53 and p21 in PLD1-or PLD2-overexpressing cells (results not shown).
ActD, a potent inducer of apoptosis in various cell types, binds to DNA and exerts growth-inhibitory effects. A previous report demonstrated that mitogenic growth factors, such as epidermal growth factor and IGF-1, protected breast cancer cells from ActD-induced cell death, suggesting that proliferation and mitogenic signalling events can protect cells from ActD-induced apoptosis [32] . The survival signalling pathway enzyme, Akt, inhibits apoptosis by blocking the apoptotic pathways at several sites, including caspase 9 [41, 42] , BAD (Bcl-2/Bcl-X L -antagonist, causing cell death) [43] , p53 [44] and glycogen synthase kinase 3 [45] . In the present study, we have shown that increased expression of either PLD1 or PLD2 resulted in potentiated activation of survival and proliferation signalling pathways involving PI3K, Akt, p70S6K and ERK at an early stage after treatment of S1P 3 -CHO cells to ActD. Prolonged activation of the PI3K-mediated signalling pathway, including Akt and p70S6K, was considered to be important for the prevention of ActD-induced apoptosis, since pretreatment of cells with LY294002, a PI3K inhibitor, completely abolished the anti-apoptotic effect of PLDs, whereas inhibition of the MEK/ERK pathway had a partial effect. Loreni et al. [46] demonstrated that transcription inhibitors, such as ActD, stimulate the translation of 5 -TOP (5 -terminal oligopyrimidine) mRNA via the activation of mTOR and the p70S6K signalling pathway. Although the exact mechanism(s) underlying the activation of these mitogenic enzymes in response to ActD is not known, results of the present study indicate that the ActD-induced activation of p70S6K is mediated via the PI3K pathway, since it was completely inhibited by LY294002.
We reported recently that PLD activation is involved in the growth factor-induced stimulation of the PI3K/Akt signalling pathway in response to S1P, but not to IGF-1 in S1P 3 -CHO cells [23] . In agreement with this, the present study has shown that PLD overexpression resulted in increased PI3K activity as well as activation of the downstream targets Akt and p70S6K at the early phase of apoptosis induced by ActD. Although the mechanism involved in the activation of survival signalling by PLD in ActDtreated S1P 3 -CHO cells is still not clear, PtdOH generated by PLD activation is considered to play a role in the stimulation of the survival signalling, since addition of 1-butanol, which prevents PLD-mediated PtdOH formation by transphosphatidylation of the reaction products to the phospholipid PtdBut, inhibited the activation of the survival signalling enzymes. Furthermore, treatment with exogenous bacterial PLD, which increases PtdOH levels, suppressed the ActD-induced apoptosis signalling pathway involving PARP and PKCδ cleavage. PtdOH is supposed to play a critical role in the PLD-mediated generation of survival and proliferation signalling events, and it has been shown to be involved both in the translocation of Raf-1 to membranes, which is important in the regulation of the ERK cascade [3] , and in the activation of mTOR, a regulator of p70S6K [2] . Recent studies have shown that the mitogenic activity of p70S6K1 requires both the mTOR and PI3K pathways, which are stimulated by PtdOH [2, 47] . Another target of PtdOH is PI4P5K, catalysing the synthesis of PtdIns(4,5)P 2 from PtdIns(4)P. PtdIns(4,5)P 2 is an essential cofactor for PLD activity and also a direct inhibitor of caspases, and overexpression of PI4P5K has been shown to suppress apoptosis [48, 49] . These results led us to speculate that, in S1P 3 -CHO cells, increased expression of PLDs in response to ActD results in increased PI4P5K activity, leading to increased PtdIns(4,5)P 2 levels. Increase in PtdIns(4,5)P 2 , which is a substrate for PI3K activity, may induce the up-regulation of PI3K activity. However, further studies are required to elucidate the exact mechanism(s) underlying the stimulation of PI3K signalling pathways by PLD.
